Aerie Pharmaceuticals, Inc (AERI) July 20, 2021 Stock Price, Analysis & Forecast
Aerie Pharmaceuticals, Inc (NASDAQ: AERI) opened the trading session on July 20, 2021, at $15.4, exhibiting a change of 2.6076% against the previous close at $15.34. Within the trading session, the stock price climbed to $16.07 and dropped to $15.27. Finally, the stock arranged at $15.74. Yet, bearing in mind a distant prospect, Aerie Pharmaceuticals, Inc reported a 52 Week Range in the range of $9.01-$21.3.
Aerie Pharmaceuticals, Inc's shares outstanding currently price $46.89M, in addition to a float of $45.80M. AERI operates in the LIFE SCIENCES sector of the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry and has a market capitalization of $738.10M (as of July 20, 2021). Also worth noting that Aerie Pharmaceuticals, Inc's 50-day Moving Average arranged at $16.11, while such value as 200-day Moving Average is presently $17.07.
To rate the company's efficiency, let's focus attention on Aerie Pharmaceuticals, Inc's conglomerate performance. As yet, AERI has full-time employees. Aerie Pharmaceuticals, Inc has generated $inf per worker Within the last fiscal year. At the same time, AERI's income per employee was $inf. And now, let's focus attention on the company's income report. Aerie Pharmaceuticals, Inc's Net Income for the last fiscal year was $-183,101,000, while such value as Income Before Taxes was at the level of $-177,856,000. AERI's Operating Income was at the mark of $-155,690,000.
Aerie Pharmaceuticals, Inc (AERI) Earnings & Revenue
Talking about the Profitability, AERI reached a Profit Margin of -205.1% and an Operating Margin (TTM) of -170.2%. However, when we touch the questions of management effectiveness, Aerie Pharmaceuticals, Inc generated a Return on Equity (TTM) of -301.1% and a Return on Assets (TTM) of -23.5%. A bit more income statements might bring clarity to our overview. According to the results of the latest quarter ended March 31, 2021, Aerie Pharmaceuticals, Inc generated Revenue (TTM) of $85.77M, reporting a Quarterly Revenue Growth of 12.9%. As for the Revenue Per Share (TTM), this indicator was at the mark of $1.865. The company's Gross Profit (TTM) was $55.50M, while according to the EBITDA report, it was estimated at $-199,219,008.
Aerie Pharmaceuticals, Inc (NASDAQ: AERI) Owners & Shares
Finally, let's take a look at the share statistics. As mentioned above, AERI's shares outstanding now amounts to $46.89M, where Shares Short was $6.09M versus the prior month amounted to $6.54M. (Short % of Float was 13.3%). And now, let's overview which kind of investors works with Aerie Pharmaceuticals, Inc's stocks. AERI's current ownership accounts for 108.62% institutional investors, while 2.397% of shares belong to the insiders. Also worth mentioning some indicators affecting dividends & splits. Thus, AERI's Forward Annual Dividend Rate is currently at the mark of 0, whereas the Dividend Yield is 0%, and a Dividend Payout Ratio is 0% (Dividend Date: December 31, 1969). The company's Dividend Per Share value thereby is $None.
AERI Trading Performance
It's time to observe the current performance indicators for Aerie Pharmaceuticals, Inc. AERI's price/earnings to growth ratio during the last reported quarter was 0%. The company's PE Ratio stands at None%, while AERI's Beta score is 0.714. Also worth noting that Aerie Pharmaceuticals, Inc's Diluted EPS (Earnings per Share) trailing twelve months is at the mark of -3.827. Other valuable indicators are Price To Sales Ratio (TTM), which is currently recorded at 8.19, as well as Price To Book Ratio, which amounts to 34.26.
Aerie Pharmaceuticals, Inc Analysis & Estimates
Within the previous 9-day period, Aerie Pharmaceuticals, Inc's Average True Range (ATR) was 0.6824, while the stock's Stochastic SlowD moving average was 37.7785%, and the SlowK moving average volumed at 37.7785%.